GSK - GlaxoSmithKline plc
| Previous Close | 41.75 |
| Open | 41.63 |
| Bid | 0.00 x 4000 |
| Ask | 0.00 x 1800 |
| Day's Range | 41.61 - 41.78 |
| 52 Week Range | 34.52 - 42.95 |
| Volume | 1,439,109 |
| Avg. Volume | 2,343,955 |
| Market Cap | 103.903B |
| Beta | 0.66 |
| PE Ratio (TTM) | 75.34 |
| EPS (TTM) | 0.55 |
| Earnings Date | Feb 1, 2017 - Feb 6, 2017 |
| Forward Dividend & Yield | 2.17 (5.29%) |
| Ex-Dividend Date | 2018-05-10 |
| 1y Target Est | 42.13 |
- American City Business Journals•3 days ago
Why GSK just inked a $330M deal with a Roivant subsidiary
GlaxoSmithKline (NYSE: GSK) and Roivant subsidiary Dermavant have inked a deal worth about $330 million. Dermavant, which has a sizable presence at Roivant’s research and development-heavy outpost in Durham, has agreed to purchase the rights to GSK’s drug tapinarof – a treatment under development for psoriasis and atopic dermatitis – and its backup programs for an initial payment of about $200 million and future milestone payment of about $130 million. “This was the result of a strategic decision to no longer focus on developing assets that are topical and exclusively a dermatology medicine,” a GSK spokeswoman said Thursday in an email. “We have been exploring opportunities to divest or partner such medicines to realize their potential value for patients and, through this process, selected Roivant and Dermavant for tapinarof.” At the end of May, Cheryl MacDiarmid, senior vice president of primary care at GSK, who leads the company’s commercial respiratory business unit in Research Triangle Park, said in an interview that the Triangle is at the center of activity as GSK shifts and broadens its cornerstone respiratory portfolio.
- American City Business Journals•3 days ago
$331M deal: GSK sells rights to experimental psoriasis drug
The buyer, Roivant subsidiary Dermavant, will make an upfront payment of $199 million to GlaxoSmithKline.
- Zacks•4 days ago
Pfizer (PFE) to Reorganize Business Into Three New Units
Pfizer (PFE) is re-organizing its business into three business segments, effective 2019. It is separating its consumer healthcare business into a standalone unit.
- Benzinga•7 days ago
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
Biotech stocks held their ground in a holiday-shortened week amid a drought of market-moving catalysts. Looking ahead, the following are catalytic events for biotech investors to watch. Conferences Fourth ...
- Market Realist•10 days ago
GlaxoSmithKline Stock’s June Performance
British multinational pharmaceutical company GlaxoSmithKline (GSK) divides its business into three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. As it is a British company, it reports its revenue in British pounds. The chart below shows GlaxoSmithKline’s revenue and EPS since Q1 2017, and analysts’ estimate for Q2 2018.
- Market Realist•11 days ago
How Novartis’s Valuation Compares
Healthcare giant Novartis (NVS) researches, develops, manufactures, and commercializes pharmaceutical products. Novartis surpassed analysts’ revenue and EPS estimates during Q1 2018, with its revenue growing 4% year-over-year to $12.7 billion from $11.5 billion at constant exchange rates. Foreign exchange boosted its revenue by 6%.
- Market Realist•11 days ago
Analysts’ Estimates and Recommendations for GSK in June
Analysts expect GlaxoSmithKline (GSK) to report revenue of ~7.1 billion British pounds during the second quarter, a 2.3% fall in year-over-year revenue compared to ~7.3 billion pounds during the second quarter of 2017. The company’s EPS are expected to be 25.96 pence during the second quarter.
- Market Realist•12 days ago
The Quarterly Performance of GSK’s Vaccines Segment
GlaxoSmithKline’s (GSK) Vaccines segment includes influenza vaccines, meningitis vaccines, Shingles vaccines, and established vaccines. The segment reported a 7% rise in YoY (year-over-year) revenue to ~1.2 billion British pounds during the first quarter. This rise followed a 13% rise in operating revenue offset by the 6% negative impact of foreign exchange during the quarter.
- Zacks•12 days ago
PFE vs. GSK: Which Stock Is the Better Value Option?
PFE vs. GSK: Which Stock Is the Better Value Option?
- Market Realist•13 days ago
The Quarterly Performances of GlaxoSmithKline’s Business Segments
GlaxoSmithKline’s (GSK) product portfolio is separated into three business segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. GlaxoSmithKline reported a rise in revenue at constant exchange rates across all three of its segments during the first quarter of 2018 compared to the first quarter of 2017. The Pharmaceuticals segment reported a 4% fall in YoY (year-over-year) revenue to ~4.0 billion British pounds during the first quarter, including a 2% rise in operating revenue offset by the 6% negative impact of foreign exchange.
- Market Realist•13 days ago
GlaxoSmithKline’s Quarterly Revenue Trend and Estimates
GlaxoSmithKline (GSK) reported revenue of ~7.2 billion British pounds in the first quarter, a 2% fall compared to the ~7.3 billion pounds it reported during the first quarter of 2017. Its revenue included a 4% rise in operating revenue, which was more than offset by the 6% negative impact of foreign exchange during the quarter. GlaxoSmithKline reports its revenues under three business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines.
- Market Realist•13 days ago
GlaxoSmithKline’s Valuation on June 29
GlaxoSmithKline (GSK) is a global pharmaceutical company with a focus on sustainable growth through strategizing its business beyond pharmaceuticals. GlaxoSmithKline reports its financial statements in British pounds.
- Financial Times•13 days ago
[$$] GSK director sued over US opioid epidemic
, the British pharmaceuticals company, has been sued by the state of Massachusetts for her alleged role in fuelling the US opioid addiction epidemic. Judy Lewent, who served on the board of opioid drugmaker Purdue Pharma for more than four years until 2014, was named as a defendant in a lawsuit filed by the state’s attorney-general last month.
- InvestorPlace•13 days ago
4 Drug and Biotech Stocks Awaiting FDA Decisions in July
It’s time to analyze how the first half turned out to be for pharma and biotech stocks in terms of FDA decisions. Key FDA approvals in the first half included Amgen (NASDAQ:AMGN)/Novartis’s first CGRP antibody Aimovig/erenumab for prevention of migraine, Johnson & Johnson’s (NYSE:JNJ) next-generation oral androgen receptor (“AR”) inhibitor Erleada (apalutamide) for pre-metastatic prostate cancer (CRPC), Vertex Pharmaceuticals’ (NASDAQ:VRTX) third medicine to treat the underlying cause of CF, Symdeko, which is a combination of tezacaftor and ivacaftor and BioMarin Pharmaceuticals’ Palynziq to treat phenylketonuria (PKU). FDA Decision on Indivior’s Schizophrenia Injection RBP-7000: On Jul 28, the FDA is expected to give its decision on Indivior‘s (OTCMKTS:INVVY) RBP-7000, which has been developed for the treatment of schizophrenia.
- Moody's•14 days ago
Novartis Securities Investment Ltd -- Moody's downgrades Novartis' rating to A1; stable outlook
Moody's Investors Service has today downgraded to A1 from Aa3 the long-term ratings of Swiss multinational pharmaceutical maker Novartis AG (Novartis) and its guaranteed subsidiaries. The outlook on the ratings is stable.
- Zacks•14 days ago
New Strong Sell Stocks for July 2nd
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
- Zacks•14 days ago
4 Drug and Biotech Stocks Awaiting FDA Decisions in July
In the first six months of the year, the FDA grants approval to 17 new treatments.
- Zacks•17 days ago
Sanofi (SNY) Finalizes Deal for European Generic Unit Sale
Sanofi (SNY) finalizes sale of its European generic unit, Zentiva, for $2.2 billion.
- Investopedia•17 days ago
Interested In Pharmaceutical Stocks? Try Novartis (ADR)
The pharmaceutical industry is the cornerstone of modern medicine in the modern capitalist world, and it is a key component to a well-diversified stock portfolio. The Novartis of today was created through a series of mergers and acquisitions, the most recent being AveXis ( AVXS) for $8.7 billion in April 2018. The company can trace its history back to the mid-18 th and 19 th centuries to two Swiss companies: CIBA, founded in 1859, and J.R. Geigy Ltd., founded in 1758.
- Zacks•17 days ago
Will a Trade War With China Wreak Havoc in US Healthcare?
It is a known fact that Chinese investments breathe life into small and mid-scale healthcare companies in America.
- Market Realist•18 days ago
A Look at Eli Lilly’s Valuations on June 25
Eli Lilly (LLY) is one of the leading global drug manufacturers, and it operates under two segments—Human Pharmaceuticals and Animal Health Products. Eli Lilly surpassed Wall Street analysts’ estimates for earnings per share and revenues for the first quarter and reported EPS of $1.34 on revenues of $5.7 billion during the quarter.
- Motley Fool•19 days ago
3 Dividend Stocks That Pay You More Than Verizon Does
Looking for companies that return big value to shareholders? Verizon checks that box, but these three stocks have it beat.
- Simply Wall St.•19 days ago
Should You Expect GlaxoSmithkline Pharmaceuticals Limited (NSE:GLAXO) To Continue Delivering An ROE Of 17.05%?
This article is intended for those of you who are at the beginning of your investing journey and want to begin learning the link between GlaxoSmithkline Pharmaceuticals Limited (NSE:GLAXO)’s returnRead More...
- Zacks•20 days ago
Roche's (RHHBY) Flu Candidate Gets Priority Review by the FDA
Roche's (RHHBY) member Genentech announces that the FDA has accepted a new drug application (NDA) and granted priority review to its baloxavir marboxil to treat patients suffering from influenza A and influenza B.
- ACCESSWIRE•20 days ago
Stock Performance Review on Pfizer and Three Other Drug Makers Stocks
Stock Research Monitor: GSK, MRK, and NVS LONDON, UK / ACCESSWIRE / June 26, 2018 / If you want a free Stock Review on PFE sign up now at www.wallstequities.com/registration . On Monday, benchmark US indices ...
